By Delilah Alvarado | September 10, 2026
The pharmaceutical landscape is often defined by its volatility, but few companies have navigated as turbulent a path as the modern-day Biohaven. Just weeks after securing a landmark licensing deal for its promising epilepsy candidate, opakalim (BHV-7000), the company has been forced to confront a significant regulatory obstacle: a partial clinical hold imposed by the U.S. Food and Drug Administration.
The hold, which pauses enrollment in the RISE-2 clinical trial, arrives at a sensitive moment for the biotech firm, casting a shadow over what was previously viewed as a strategic financial masterstroke. For investors and patients alike, the development raises urgent questions about the regulatory pathway for a drug that is intended to serve as a cornerstone of the company’s future portfolio.
Main Facts: The Clinical Hold Explained
The FDA’s decision to place a partial hold on the clinical development of opakalim centers on concerns regarding a specific metabolite associated with the drug. While the details of the concern remain technical, the regulatory action effectively stalls the enrollment of new patients in the RISE-2 study—a pivotal trial designed to evaluate the drug’s efficacy in treating focal epilepsy.
Biohaven has emphasized that the drug has been administered to more than 1,200 patients to date, with the company maintaining that the therapy remains "well-tolerated." Despite this, the FDA’s intervention signals a requirement for further data before the trial can resume full-scale recruitment. This development is particularly critical because analysts consider the data from the RISE-2 trial to be a fundamental prerequisite for any eventual New Drug Application (NDA) filing.
Chronology: A History of High Stakes
To understand the weight of this setback, one must look at the recent trajectory of Biohaven. The current entity is the second iteration of a firm that famously sold its initial migraine business to Pfizer in 2022 for $11.6 billion. Following that acquisition, the leadership team, headed by CEO Vlad Coric, immediately spun out a new company—retaining the Biohaven name—with a fresh, ambitious pipeline.
The years since have been defined by a relentless, if sometimes rocky, quest to replicate that early success:
- 2022–2023: The "new" Biohaven aggressively pursues indications in rare diseases and neuropsychiatry, aiming to build a diverse clinical engine.
- 2024: The company faces a series of clinical disappointments, including a controversial rejection by the FDA for its drug vyglyxia (troriluzole) in spinocerebellar ataxia, and failures in trials for spinal muscular atrophy and depression.
- 2025: Facing dwindling cash reserves, Biohaven undergoes significant restructuring, slashing R&D expenditures and shifting scientific leadership to focus on high-probability assets.
- August 2026: Biohaven inks a $795 million deal with South Korea’s SK Biopharmaceuticals, granting them rights to opakalim. The deal provides a critical $350 million upfront cash infusion, allowing Biohaven to extend its operational runway.
- September 2026: The FDA issues a partial clinical hold on the opakalim program, citing metabolite data, halting new enrollments in the RISE-2 study.
Supporting Data and Strategic Context
The financial logic behind the SK Biopharmaceuticals deal was widely praised by Wall Street as a necessary hedge. Minter, an analyst at William Blair, described the transaction as "prudent but necessary," noting that while it capped the total upside for Biohaven, it provided the liquidity required to keep the company’s broader research efforts afloat.
Biohaven’s management has been quick to point out that full clinical and nonclinical data packages were shared with SK Biopharmaceuticals prior to the deal’s execution. This disclosure, they argue, suggests that their partners were already aware of the potential for regulatory scrutiny regarding the metabolite. In a regulatory filing, Biohaven noted, "We provided all available data to our partners, and they expressed comfort with the profile of the asset."
However, the scientific premise of opakalim remains a subject of intense scrutiny. Originally designed as a potassium channel modulator, it is intended to provide a more selective, targeted treatment for epilepsy than current standards of care. While it failed to meet primary endpoints in a major depressive disorder trial, the company successfully pivoted its narrative, repositioning the drug as a high-potential treatment for focal epilepsy and neuropathic pain.
Official Responses and Stakeholder Sentiment
Biohaven has remained publicly optimistic, framing the hold as a standard part of the regulatory engagement process rather than a death knell for the drug. The company is actively working with the FDA to address the data request, which is expected to involve additional analytical modeling or perhaps further preclinical evidence regarding the metabolite’s impact.
Analysts, however, are taking a more cautious view. RBC Capital Markets analyst Leonid Timashev noted that the hold introduces "significant execution risk." He argued that while the company may be able to resolve the FDA’s concerns, any requirement for additional, unexpected clinical trials could lead to a substantial delay in the timeline to market. Furthermore, the risk of a "concerning signal" emerging from the deeper data analysis remains a persistent fear among institutional investors.
Implications: The Road Ahead
The implications of this hold are multi-faceted, affecting both the clinical timeline and the company’s market valuation.
1. The Regulatory Burden
The FDA’s request for additional data effectively puts Biohaven on the clock. If the company can address the metabolite concern with existing data, the pause may be short-lived. If, however, the FDA demands a new, prospective study to prove safety, the cost and time requirements could jeopardize the company’s carefully managed cash position.
2. The Partnership Dynamic
The relationship between Biohaven and SK Biopharmaceuticals will be tested. If the hold persists, it could complicate the collaborative research efforts and milestones established in the licensing agreement. Trust in the data transparency—already a point of contention in biotech deals—will be under the microscope.
3. Investor Confidence
Biohaven has spent much of 2025 and 2026 attempting to restore investor confidence after a string of high-profile clinical misses. A hold on its most promising remaining asset is a significant blow to the "innovation engine" narrative the company has promoted to shareholders. The stock’s performance in the coming weeks will likely depend on how quickly management can provide a concrete timeline for lifting the hold.
4. The Patient Impact
For the epilepsy community, the delay is a tangible setback. Selective potassium channel modulators like opakalim represent a potentially transformative approach to seizure control for patients who have not responded to traditional anti-epileptic drugs. Every day that the RISE-2 trial remains in limbo is a day that these patients are denied access to a potentially life-altering therapy.
Conclusion
Biohaven finds itself at a familiar crossroads. The company has demonstrated a remarkable ability to raise capital and restructure its operations, yet the underlying reality remains: in the biotech industry, financial ingenuity can only go so far without consistent clinical success. The partial hold on opakalim is a stark reminder that even with sophisticated science and a strategic partner, the final arbiter is the regulatory process. Whether this is merely a temporary speed bump or the beginning of a more difficult chapter for the company will be determined by the data Biohaven presents to the FDA in the coming months. For now, the "innovation engine" is idling, and the industry is watching closely to see if it can restart.
About the Author
